Evidence map›Paper›PMID 26209116›Full record

ReviewVeterinary immunology and immunopathology2015

Innate and adaptive immunity against Porcine Reproductive and Respiratory Syndrome Virus.

Crystal L Loving, Fernando A Osorio, Michael P Murtaugh, Federico A Zuckermann

Abstract readReview
In one paragraph

Review in Veterinary immunology and immunopathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers.

0numbers the graph read from it
0cells of the map it votes in
109citing papers in PubMed
21.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

109 citing papers in PubMed, 200 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

49 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Crystal L LovingUSDA-ARS-National Animal Disease Center, Ames, IA, United States. Electronic address: crystal.loving@ars.usda.gov.
Fernando A OsorioNebraska Center for Virology and School of Veterinary & Biomedical Sciences, University of Nebraska-Lincoln, United States.
Michael P MurtaughDepartment of Veterinary and Biomedical Sciences, University of Minnesota, St. Paul, MN, United States.
Federico A ZuckermannDepartment of Pathobiology, College of Veterinary Medicine, University of Illinois, Urbana-Champaign, IL, United States.
National Animal Disease Center · USUniversity of Illinois Urbana-Champaign · USUniversity of Minnesota · USUniversity of Nebraska–Lincoln · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many highly effective vaccines have been produced against viruses whose virulent infection elicits strong and durable protective immunity. In these cases, characterization of immune effector mechanisms and identification of protective epitopes/immunogens has been informative for the development of successful vaccine programs. Diseases in which the immune system does not rapidly clear the acute infection and/or convalescent immunity does not provide highly effective protection against secondary challenge pose a major hurdle for clinicians and scientists. Porcine reproductive and respiratory syndrome virus (PRRSV) falls primarily into this category, though not entirely. PRRSV causes a prolonged infection, though the host eventually clears the virus. Neutralizing antibodies can provide passive protection when present prior to challenge, though infection can be controlled in the absence of detectable neutralizing antibodies. In addition, primed pigs (through natural exposure or vaccination with a modified-live vaccine) show some protection against secondary challenge. While peripheral PRRSV-specific T cell responses have been examined, their direct contribution to antibody-mediated immunity and viral clearance have not been fully elucidated. The innate immune response following PRRSV infection, particularly the antiviral type I interferon response, is meager, but when provided exogenously, IFN-α enhances PRRSV immunity and viral control. Overall, the quality of immunity induced by natural PRRSV infection is not ideal for informing vaccine development programs. The epitopes necessary for protection may be identified through natural exposure or modified-live vaccines and subsequently applied to vaccine delivery platforms to accelerate induction of protective immunity following vaccination. Collectively, further work to identify protective B and T cell epitopes and mechanisms by which PRRSV eludes innate immunity will enhance our ability to develop more effective methods to control and eliminate PRRS disease.

Indexed as

Adaptive ImmunityAnimalsAntibodies, NeutralizingAntibodies, ViralAntigens, ViralCross ReactionsEpitopesHost-Pathogen InteractionsImmune EvasionImmunity, CellularImmunity, InnatePorcine Reproductive and Respiratory SyndromePorcine respiratory and reproductive syndrome virusSus scrofaSwineT-LymphocytesAntibodies, NeutralizingAntibodies, ViralAntigens, ViralEpitopesViral VaccinesAntibodyCell-mediated immunityImmunologyInnate immunityPRRSV

Identifiers

PMID26209116
PMCPMC7112826
OpenAlexW970789458

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.